GlyNAC: The Glycine + NAC Stack Backed by Human Aging Trials (2026)

Most longevity supplements target one hallmark of aging. You take an NAD+ precursor for mitochondrial function. You take a senolytic for zombie cells. You take an anti-inflammatory for chronic inflammation.

Then there is GlyNAC – a combination of two cheap amino acid precursors (glycine and N-acetylcysteine) that, in a single randomized controlled trial at Baylor College of Medicine, simultaneously improved oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, physical function, cognition, genomic damage, and gait speed in older adults. Glutathione levels, which had been roughly half those of young controls, returned to young-adult levels within 16 weeks.

That is not typical for a supplement. It is barely typical for a pharmaceutical.

This article breaks down the GlyNAC research in full – what it is, how it works, what the Baylor trials actually found, how to dose it, and why two amino acids that cost less than a dollar a day may be among the most impactful longevity interventions available.

TL;DR

• GlyNAC is a combination of glycine and N-acetylcysteine (NAC) – the two rate-limiting precursors for glutathione synthesis

Quick Facts: GlyNAC

• Dose: ~7g glycine + ~7g NAC/day (100mg/kg each)
• Form: Powder (split 2-3x daily)
• Timing: Divided doses throughout the day
• Evidence: Strong (Baylor RCT, 2023)
• Who it's for: Adults 60+ with glutathione decline, oxidative stress, or age-related metabolic dysfunction
• Glutathione (your body's master intracellular antioxidant) declines 40-50% by age 60+, driven by substrate deficiency
• The 2023 Baylor RCT (Kumar et al., n=36 older + 12 young adults, 16 weeks) showed GlyNAC restored glutathione to young-adult levels and improved 8+ aging biomarkers simultaneously
• Earlier 2021 pilot (n=24) showed similar results over 24 weeks – with benefits reversing within 12 weeks of stopping
• Mechanism: glycine and cysteine (from NAC) are the two limiting building blocks your body needs to synthesize glutathione – supplementing both restores the supply chain
• Study dose: glycine 1.33 mmol/kg/day + NAC 0.81 mmol/kg/day (~100 mg/kg each, roughly 7g + 7g for a 70 kg person)
• OTC, affordable (~$0.50-1.00/day), and well-tolerated
• GlyNAC outperforms NAC alone or oral glutathione supplements for restoring endogenous glutathione levels

What Is GlyNAC?

GlyNAC is not a branded supplement or a patented formula. It is a research shorthand for two compounds taken together:

1. Glycine – the simplest amino acid in the human body. It serves as a building block for collagen, a precursor for glutathione, and a substrate for creatine and heme synthesis. For a deep dive on glycine's individual longevity roles, see Glycine: The Simplest Amino Acid With the Biggest Longevity Impact.
2. N-acetylcysteine (NAC) – an acetylated form of the amino acid cysteine. NAC is a well-studied compound that has been used clinically for decades as a mucolytic (mucus-thinning agent) and as the antidote for acetaminophen overdose. In the GlyNAC context, its role is simpler: it provides cysteine, the most rate-limited of the three amino acids needed to build glutathione.

Together, glycine and NAC supply the two amino acid precursors that become scarce with age – restoring the raw materials your cells need to manufacture glutathione on their own.

This distinction matters. GlyNAC does not deliver glutathione directly. It enables your body to synthesize it endogenously (internally). This is a fundamentally different and more effective approach than swallowing glutathione itself, for reasons we will cover.

The Glutathione Problem: Why Your Master Antioxidant Collapses With Age

Glutathione (abbreviated GSH) is the most abundant intracellular antioxidant in the human body. It is present in virtually every cell, with concentrations in the millimolar range – orders of magnitude higher than circulating antioxidants like vitamin C or vitamin E. It is sometimes called the "master antioxidant" not because of marketing, but because of its unique biochemistry.

What Glutathione Does

Glutathione performs several functions that no other molecule can fully replace:

• Direct antioxidant defense. GSH neutralizes reactive oxygen species (ROS) – chemically reactive molecules containing oxygen that damage DNA, proteins, and cell membranes. The enzyme glutathione peroxidase uses GSH to convert hydrogen peroxide into water.
• Recycling other antioxidants. Glutathione regenerates vitamin C and vitamin E after they have been "spent" neutralizing free radicals. Without glutathione, these antioxidants cannot be recycled and the entire antioxidant defense network degrades.
• Detoxification. The liver uses glutathione to conjugate (chemically attach to) toxins, drugs, and metabolic waste products, making them water-soluble for excretion. This is why acetaminophen overdose depletes glutathione catastrophically – and why NAC (a glutathione precursor) is the clinical antidote.
• Immune regulation. T-cells and natural killer cells require adequate glutathione to proliferate and function. Glutathione depletion is associated with impaired immune response across multiple studies.
• Mitochondrial protection. Mitochondria – the organelles that generate ATP (cellular energy) – produce ROS as a byproduct of energy production. Mitochondrial glutathione is the primary defense against this self-generated oxidative damage. For more on why mitochondrial function declines with age, see The Mitochondrial Theory of Aging.

The Age-Related Decline

Here is the problem. Glutathione levels decline significantly with age – by approximately 40-50% in adults over 60 compared to young adults.

This was documented directly in the Baylor GlyNAC research. At baseline, older adults in the 2023 trial had red blood cell glutathione concentrations approximately 66% lower than the young control group (Kumar et al., 2023, Journals of Gerontology). Similar magnitude declines have been reported in multiple independent studies across different tissues.

The decline is not random. It correlates with – and likely drives – increases in multiple hallmarks of aging: oxidative stress rises, mitochondrial function deteriorates, chronic inflammation increases, and DNA damage accumulates. These are not independent problems. They are downstream consequences of a failing antioxidant defense system.

Why Glutathione Declines: The Substrate Bottleneck

The critical question is: why does glutathione decline with age? The answer is not that cells lose the ability to make it. The enzymes responsible for glutathione synthesis – glutamate-cysteine ligase (GCL, the rate-limiting enzyme) and glutathione synthetase (GS) – remain active in aging cells.

The problem is substrate availability. Glutathione is a tripeptide (a molecule made of three amino acids linked together): glutamate, cysteine, and glycine. Of these three:

• Glutamate is abundant in the body and rarely limiting.
• Cysteine is the most rate-limited precursor. Free cysteine is unstable and poorly absorbed from the diet. Intracellular cysteine concentrations decline with age.
• Glycine is the second limiting precursor. Endogenous glycine synthesis falls short of metabolic demand by an estimated 10g/day even in healthy adults (Melendez-Hevia et al., 2009, Journal of Biosciences), and this deficit widens with age as collagen turnover, creatine synthesis, and detoxification all compete for the same limited supply.

This is the substrate bottleneck hypothesis: glutathione declines not because cells cannot make it, but because they run out of the raw materials. If you restore those raw materials – glycine and cysteine – cells resume glutathione synthesis on their own.

That is exactly what the Baylor GlyNAC trials tested.

Key Takeaway: Glutathione is your body's master antioxidant — present in every cell, responsible for neutralizing ROS, recycling other antioxidants, and supporting detoxification. It declines 40-50% between ages 20 and 80, not because synthesis machinery fails, but because the precursor amino acids (glycine and cysteine) become deficient. GlyNAC directly addresses this bottleneck.

The Baylor Trials: From Pilot to Randomized Controlled Trial

The GlyNAC research program was led by Dr. Rajagopal Sekhar at Baylor College of Medicine in Houston, Texas. It progressed from an open-label pilot to a full randomized controlled trial – the gold standard of clinical evidence.

The Pilot Study (2021)

Kumar P, Liu C, Hsu JW, et al. (2021). Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition. Clinical and Translational Medicine, 11(3), e372.

Design:

• Open-label pilot clinical trial (no placebo control, no blinding)
• 16 older adults (61-80 years) and 8 young adults (21-40 years)
• Older adults received GlyNAC for 24 weeks, followed by a 12-week washout period
• Young adults served as baseline comparators (did not receive supplementation)
• Dose: glycine 1.33 mmol/kg/day + NAC 0.81 mmol/kg/day (approximately 100 mg/kg/day of each)

Key Findings:

• Glutathione levels in older adults were 66% lower than young adults at baseline – and fully restored to young adult levels after 24 weeks of GlyNAC
• Oxidative stress markers (TBARS, F2-isoprostanes) decreased to match young adult levels
• Mitochondrial fatty acid oxidation (the process by which mitochondria burn fat for fuel) improved significantly
• Markers of inflammation (IL-6, TNF-alpha, CRP) decreased
• Insulin resistance (measured by HOMA-IR, a standard clinical index) improved
• Endothelial dysfunction (impaired function of blood vessel lining) improved
• Genomic damage (measured by 8-OHdG, a marker of oxidative DNA damage) decreased
• Muscle strength (grip strength) and gait speed improved
• Cognition improved on multiple standard tests

The Washout: This was one of the most informative aspects of the pilot. After participants stopped taking GlyNAC, benefits reversed within 12 weeks. Glutathione levels dropped back down. Oxidative stress markers rose. The improvements were not permanent – they depended on continued supplementation.

This suggests that GlyNAC is not "fixing" a broken enzyme or repairing a permanent defect. It is restoring a supply chain. When the supply stops, the deficiency returns.

Limitations of the Pilot: The pilot was open-label (not blinded) and had no placebo group. This means placebo effects could not be ruled out. The sample size was small (16 older adults). These are legitimate limitations – which is why the same group conducted a proper RCT.

The Randomized Controlled Trial (2023)

Kumar P, Osahon OW, Sekhar RV. (2023). Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. The Journals of Gerontology: Series A, 78(1), 75-89.

Design:

• Randomized, double-blind, placebo-controlled trial – the gold standard
• 36 older adults (61-80 years) randomized to GlyNAC or placebo (alanine, a neutral amino acid)
• 12 young adults (21-40 years) as non-supplemented comparators
• 16 weeks of supplementation (shorter than the pilot's 24 weeks)
• Same dose: glycine 1.33 mmol/kg/day + NAC 0.81 mmol/kg/day

Key Results – Older Adults on GlyNAC vs. Placebo:

What the Placebo Group Showed: The placebo group (receiving alanine) showed no significant improvement on any measured outcome. This is critical – it rules out the possibility that simply taking "any amino acid" would produce these effects.

What the Young Control Group Showed: The young adults (who received nothing) already had high glutathione levels, low oxidative stress, and good metabolic function. The GlyNAC group's post-supplementation values converged with the young group's baseline values across most outcomes. In other words, GlyNAC did not just improve things – it restored them to young-adult levels.

Key Takeaway: The 2023 Baylor RCT (n=36, 16 weeks) is the strongest evidence yet: GlyNAC supplementation in older adults corrected glutathione deficiency and improved oxidative stress, mitochondrial function, inflammation, insulin resistance, endothelial function, body composition, exercise capacity, and cognitive function. Eight hallmarks of aging improved with two amino acids.

What Improved: The Full Biomarker Breakdown

The breadth of the GlyNAC findings is what makes them unusual. Most interventions in aging research improve one or two biomarkers. The 2023 RCT showed improvement across at least eight distinct categories – all from the same two-ingredient intervention.

1. Glutathione Levels

The primary outcome. Red blood cell glutathione concentrations were approximately 66% lower in older adults at baseline. After 16 weeks of GlyNAC, levels were statistically indistinguishable from the young control group. The placebo group showed zero change.

2. Oxidative Stress

Plasma TBARS (thiobarbituric acid reactive substances, a measure of lipid peroxidation – damage to cell membrane fats caused by free radicals) and F2-isoprostanes (another lipid peroxidation marker) both decreased significantly. These markers reflect the real-time burden of oxidative damage in the body.

3. Mitochondrial Function

Mitochondrial fatty acid oxidation – measured by stable isotope tracers, a gold-standard technique – improved significantly. This means the mitochondria were generating energy more efficiently from fat, a capacity that degrades with age and is linked to metabolic dysfunction. For context on why mitochondrial decline matters, see The Mitochondrial Theory of Aging.

4. Inflammation

Interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), two of the most widely measured markers of chronic low-grade inflammation (sometimes called "inflammaging"), both decreased in the GlyNAC group. C-reactive protein (CRP) trended downward as well. This is noteworthy because chronic inflammation is both a hallmark of aging and a driver of age-related disease.

5. Insulin Resistance

HOMA-IR (Homeostatic Model Assessment for Insulin Resistance, calculated from fasting glucose and insulin levels) improved in the GlyNAC group. Insulin resistance – where cells become progressively less responsive to insulin's signal to take up glucose – is a core driver of metabolic syndrome, type 2 diabetes, and cardiovascular disease. This improvement occurred without any dietary or exercise changes.

6. Physical Function

Three distinct measures of physical function improved:

• Gait speed – how fast participants walked at their normal pace. Gait speed is one of the strongest predictors of all-cause mortality in older adults; the correlation is so robust that some geriatricians call it "the sixth vital sign."
• Grip strength – a standard clinical measure of upper body and overall muscle function.
• Exercise capacity – measured by the 6-minute walk test, a validated assessment of cardiovascular and musculoskeletal fitness.

7. Cognition

Participants showed improvement on standardized cognitive assessments including tests of processing speed, memory, and executive function. While the cognitive improvements need replication in larger, longer trials, the direction is consistent with the known role of oxidative stress and glutathione depletion in cognitive decline.

8. Genomic Damage

8-hydroxydeoxyguanosine (8-OHdG), a marker of oxidative damage to DNA, decreased significantly. This is important because accumulated DNA damage is one of the twelve hallmarks of aging and a driver of cellular dysfunction, mutations, and cancer risk.

9. Body Composition and Cardiovascular Markers

BMI, waist circumference, and systolic blood pressure all showed modest but statistically significant improvements. These secondary outcomes suggest systemic metabolic benefits beyond the core oxidative stress/glutathione pathway.

The Mechanism: How Two Amino Acids Reverse Multiple Aging Markers

The breadth of the results can seem implausible until you understand the mechanism. GlyNAC does not have eight separate pharmacological effects. It has one: restoring glutathione synthesis.

Here is the chain of events:

Step 1: Substrate Restoration. Glycine and NAC provide the two rate-limiting precursors (glycine and cysteine) for glutathione synthesis. NAC is deacetylated (the acetyl group is removed) intracellularly to release free cysteine, which is otherwise unstable and poorly absorbed.

Step 2: Glutathione Synthesis Resumes. With adequate substrates available, the enzymes glutamate-cysteine ligase (GCL) and glutathione synthetase (GS) resume normal-rate glutathione production. These enzymes were never broken – they were just substrate-starved.

Step 3: Antioxidant Defense Restored. Intracellular glutathione rises. ROS are neutralized more efficiently. Lipid peroxidation decreases. Oxidative DNA damage decreases. Vitamin C and E are recycled again.

Step 4: Downstream Systems Recover. With oxidative stress reduced:

• Mitochondria sustain less oxidative damage, so their function improves
• NF-kB activation (a key inflammatory signaling pathway triggered in part by ROS) decreases, reducing inflammatory cytokines
• Insulin signaling improves (ROS directly impair insulin receptor signaling)
• DNA repair mechanisms work more efficiently when not overwhelmed by ongoing oxidative damage
• Physical and cognitive function improve as the tissues supporting them operate under less oxidative burden

This is a cascade effect: one upstream fix -- restoring glutathione -- propagates improvements across every system that glutathione protects. And since glutathione protects essentially every cell in the body, the effects are broad.

This also explains why the benefits reversed during the washout period. Stop supplying the substrates and the bottleneck returns. Glutathione drops. Oxidative stress rises. Everything downstream degrades again.

Understanding this mechanism is essential for interpreting the results correctly. GlyNAC is not a polypharmacy cocktail that targets eight different pathways. It is a substrate replenishment strategy that fixes one bottleneck with broad downstream consequences.

For more on how upstream metabolic signals control multiple aging pathways simultaneously, see mTOR and AMPK: The Two Switches That Control How You Age.

Key Takeaway: GlyNAC reversed all four mitochondrial defects measured in the trial: impaired fuel oxidation, increased free radical production, reduced membrane potential, and lower ATP generation. Mitochondrial function was restored to levels comparable to younger controls within 16 weeks — one of the most dramatic mitochondrial rescue results documented in a human supplement trial.

GlyNAC vs. NAC Alone vs. Oral Glutathione

A natural question: if the goal is to restore glutathione, why not just take glutathione directly? Or just take NAC, which is already widely available?

Why NAC Alone Falls Short

NAC is one of the most popular supplements in the longevity space. It provides cysteine, the most rate-limited glutathione precursor. And it does raise glutathione levels – modestly.

But NAC alone addresses only half the substrate problem. If glycine is also limiting – and the Baylor data clearly shows it is in older adults – then providing cysteine alone is like filling only one of the two empty tanks your engine needs to run. You get partial improvement, not full restoration.

The 2023 RCT did not include an NAC-only arm, so we cannot directly compare within that study. However, the magnitude of the glutathione restoration achieved with GlyNAC (to young-adult levels) exceeds what has been demonstrated with NAC alone in comparable populations. The combination addresses both rate-limiting substrates simultaneously, which is why the results are more comprehensive.

Why Oral Glutathione Is Problematic

You can buy glutathione supplements. They come in capsules, liposomal formulations, and sublingual forms. But there are fundamental problems with this approach:

1. Poor oral bioavailability. Glutathione is a tripeptide. When ingested orally, it is largely broken down by peptidases (enzymes that cleave peptide bonds) in the GI tract before reaching the bloodstream. Standard oral glutathione has very low bioavailability.
2. Liposomal glutathione is better but limited. Liposomal formulations (where glutathione is encapsulated in lipid spheres) improve absorption and have been shown to raise blood glutathione levels in some studies. But this approach delivers glutathione to the blood – not necessarily to intracellular compartments where it is needed.
3. It bypasses the endogenous system. Even if you successfully deliver glutathione to cells, you have not addressed the underlying problem – the substrate deficiency. If you stop taking glutathione, levels crash immediately because your body's own synthesis is still impaired. GlyNAC, by contrast, restores your body's ability to produce glutathione on its own. The underlying machinery is repaired (more precisely, re-fueled), not bypassed.
4. Cost. Quality liposomal glutathione costs $40-80/month. GlyNAC costs $15-30/month.

Why Both Precursors Are Needed

The Sekhar group's insight – which the data validates – is that aging glutathione deficiency is a dual-substrate problem, not a single-substrate problem. Earlier research focused almost exclusively on cysteine/NAC. Adding glycine to the equation is what unlocked the dramatic, comprehensive results seen in the trials.

Think of it this way: glutathione synthesis is an assembly line with two inputs that become scarce. Flooding the factory with only one input does not restore full production. You need both.

Dosing: What the Studies Used

The GlyNAC dose used in both the 2021 pilot and the 2023 RCT was weight-based:

• Glycine: 1.33 mmol/kg/day (approximately 100 mg/kg/day)
• NAC: 0.81 mmol/kg/day (approximately 100 mg/kg/day)

What This Means in Practice

These are substantial doses – 7g of each for an average-weight adult means 14g of total amino acid powder daily. This is not a "take two capsules" intervention. Most people using the GlyNAC protocol take it as powder mixed into water or dissolved in food.

Timing

The clinical trials used divided doses (split across the day), but did not specify rigid timing. A practical approach:

• Split the daily dose into 2-3 servings
• Take with or without food (both amino acids are well-absorbed either way)
• If taking glycine for sleep as well, allocate 3g of the glycine portion to the evening dose

Ramp-Up

Neither study used a ramp-up protocol, but some practitioners recommend starting at half-dose for the first week to assess GI tolerance, particularly with NAC, which can cause nausea in some individuals at higher doses.

Duration

The 2023 RCT used 16 weeks and achieved full glutathione restoration. The 2021 pilot used 24 weeks with similar results. The washout data from the pilot showed benefits reversing within 12 weeks, suggesting this is an ongoing supplementation strategy, not a short course.

Lower Doses

No published trial has tested lower GlyNAC doses (e.g., 3g + 3g daily) to determine whether partial benefits are achievable. This is a gap in the literature. It is plausible that lower doses would provide partial glutathione restoration, but this has not been confirmed.

Safety and Side Effects

Drug Interaction Warning: NAC may interact with nitroglycerin (causing blood pressure drops) and some chemotherapy agents. Glycine may interact with clozapine due to shared NMDA receptor activity. People with asthma should use caution with NAC. Consult your physician if you take any prescription medications before starting GlyNAC.

Both glycine and NAC have well-established safety profiles from decades of clinical use.

Glycine

• No serious adverse events reported in clinical trials at doses up to 15 g/day
• Mild GI discomfort (bloating, soft stool) is the most common side effect, typically at high single doses (>10 g at once)
• Glycine has mild hypoglycemic effects – potentially relevant for people on diabetes medications
• Drug interaction: glycine may interact with clozapine (an antipsychotic) due to shared NMDA receptor activity

NAC

• NAC has been used clinically for over 50 years (as a mucolytic and acetaminophen antidote)
• Common side effects: nausea, vomiting, and diarrhea, particularly at doses above 1,200 mg/day taken on an empty stomach
• NAC has a strong sulfuric taste and smell that some people find unpleasant
• Rare: rash, bronchospasm (in people with asthma – primarily with inhaled NAC)
• Drug interactions: NAC may interact with nitroglycerin (blood pressure drop) and some chemotherapy agents

GlyNAC Combined (from the Baylor Trials)

• In both the 2021 and 2023 studies, GlyNAC was described as "well-tolerated"
• No serious adverse events were reported in either trial
• The most common complaint was mild GI discomfort

Who Should Avoid GlyNAC

• Individuals with active kidney disease (high amino acid loads require renal clearance)
• People taking nitroglycerin or other nitrate medications (NAC interaction)
• Those with known NAC sensitivity or sulfa-related sensitivities (though NAC is not a sulfonamide, some individuals report cross-reactivity)
• Anyone on chemotherapy should consult their oncologist (antioxidants may theoretically interfere with some treatment mechanisms, though evidence is mixed)

As with any supplement regimen, consult a healthcare provider before starting, particularly if you take prescription medications.

Limitations and Open Questions

The GlyNAC research is promising, but intellectual honesty requires acknowledging what we do not know:

Sample Size

The 2023 RCT included 36 older adults (18 per arm). This is a small trial by pharmaceutical standards. The consistency of results across multiple biomarkers and between the pilot and the RCT is reassuring, but replication in larger cohorts is needed.

Population

Both studies enrolled generally healthy older adults (61-80 years) without serious chronic disease. It is unknown whether GlyNAC would produce similar results in people with established diabetes, cardiovascular disease, or other age-related conditions.

Duration

Sixteen weeks showed full glutathione restoration, but we do not know the effects of 1, 2, or 5 years of continuous GlyNAC supplementation. Long-term safety data at these doses does not exist.

Dose-Response

No lower-dose arms were included. Whether 3g + 3g (instead of 7g + 7g) would provide partial benefit is unknown. This is practically important because the full protocol dose requires substantial daily powder intake.

Mortality and Disease Outcomes

The trials measured biomarkers and functional outcomes. No trial has been powered to detect whether GlyNAC reduces the incidence of heart disease, cancer, dementia, or mortality. Biomarker improvements are encouraging, but they are not proof of disease prevention.

Single Research Group

Both the pilot and the RCT came from the same lab (Sekhar group at Baylor). Independent replication by other research groups would significantly strengthen confidence in the findings. As of March 2026, independent replication of the full GlyNAC protocol in a comparably rigorous design has not been published.

Mechanism Specificity

The broad improvements could be driven entirely by glutathione restoration (as proposed), but the studies did not include a direct glutathione supplementation arm for comparison. It is theoretically possible that glycine and NAC have independent benefits beyond glutathione that contribute to the results.

No Head-to-Head Comparisons

There is no published trial comparing GlyNAC to NAC alone, glycine alone, or liposomal glutathione in the same population with the same endpoints. The superiority of the combination over its individual components is mechanistically plausible but not directly proven in a single trial.

How to Track Whether GlyNAC Is Working

If you start a GlyNAC protocol, standard blood tests can help you track relevant markers. For a full guide on biological age testing, see Biological Age Testing: The Complete Guide.

Relevant markers to discuss with your physician:

• Glutathione (RBC) – directly measures what GlyNAC is meant to restore. Requires a specific red blood cell glutathione assay (not all labs offer this routinely).
• hs-CRP – high-sensitivity C-reactive protein, a widely available inflammatory marker.
• Fasting glucose and insulin (HOMA-IR) – tracks insulin resistance changes.
• 8-OHdG – oxidative DNA damage marker (specialty test).
• Basic lipid panel and metabolic panel – for general metabolic health monitoring.

Functional measures like grip strength and gait speed can be tracked at home without bloodwork. For an evidence-based ranking of GlyNAC's component compounds alongside other longevity interventions, see the Compound Index.

Frequently Asked Questions

Related Reading

• Glycine: The Simplest Amino Acid With the Biggest Longevity Impact
• The Mitochondrial Theory of Aging: Why Your Cellular Power Plants Matter
• Inflammaging: The Chronic Inflammation That Drives Every Aging Hallmark
• The 12 Hallmarks of Aging: Why You Age and What Targets Each One
• Biological Age Testing: The Complete Guide to Measuring How Fast You're Aging
• Taurine and Aging: What the Science Actually Says

References:

1. Kumar P, Liu C, Hsu JW, et al. (2021). Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition. Clinical and Translational Medicine, 11(3), e372.
2. Kumar P, Osahon OW, Sekhar RV. (2023). Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. The Journals of Gerontology: Series A, 78(1), 75-89.
3. Meléndez-Hevia E, De Paz-Lugo P, Cornish-Bowden A, Cárdenas ML. (2009). A weak link in metabolism: the metabolic capacity for glycine biosynthesis does not satisfy the need for collagen synthesis. Journal of Biosciences, 34(6), 853-872.
4. Sekhar RV, Patel SG, Guthikonda AP, et al. (2011). Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation. American Journal of Clinical Nutrition, 94(3), 847-853.
5. Sekhar RV. (2022). GlyNAC (Glycine and N-Acetylcysteine) Supplementation Improves Impaired Mitochondrial Fuel Oxidation and Lowers Insulin Resistance in Patients with Type 2 Diabetes: Results of a Pilot Study. Antioxidants, 11(1), 154.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.